HBMHF (HBM Holdings) Tariff Resilience Score: 6/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBMHF HBM Holdings Ltd HBMHF
73 GF Score
Price $1.56
GF Value $0.87
! 4 Warning Signs
View Full Analysis

What is HBM Holdings Tariff Resilience Score?

HBM Holdings HBMHF 73 Tariff Resilience Score is 6 as of Jul. 30, 2026. GuruFocus rates HBMHF with a GF Score™ of 73/100 and a GF Value™ of $0.87. The stock has 4 warning signs investors should review. Among 1,368 Biotechnology companies, HBM Holdings ranks better than 76.02% on this metric.

HBM Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

HBM Holdings has Diversified holdings with some exposure to international trade. Moderate tariff impact, mitigated by diversified portfolio and potential for strategic supplier adjustments.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes HBM Holdings might have Average Resilient.

HBM Holdings  (OTCPK:HBMHF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

HBM Holdings Tariff Resilience Score Related Terms

HBMHF vs VRTX, REGN, RVMD: Tariff Resilience Score Comparison

For the Biotechnology subindustry, HBM Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Tariff Resilience Score falls into.


HBMHF
73GF Score
HBM Holdings Ltd HBMHF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
HBM Holdings (HBMHF) has a Tariff Resilience Score of 6 as of Jul. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, HBM Holdings ranks #328 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is HBM Holdings' Tariff Resilience Score too high?
HBM Holdings' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. HBM Holdings' value of 6 is 50% above this industry median. Based on the distribution chart, HBM Holdings ranks #328 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #328 out of 1368 companies for Tariff Resilience Score. This places HBM Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. HBM Holdings' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
HBM Holdings (HBMHF) has a current Tariff Resilience Score of 6. The stock's GF Value™ is $0.87, compared to a current price of $1.56 — trading 79.3% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For HBM Holdings (HBMHF), the current Tariff Resilience Score is 6 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HBM Holdings (HBMHF) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of $1.56 is trading 79.3% above its estimated GF Value™ of $0.87.

Key valuation signals for HBMHF:

  • Tariff Resilience Score: 6
  • GF Value™: $0.87 vs. price of $1.56 (79.3% above fair value)
  • GF Score™: 73/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#328 of 1368)

No single metric tells the full story. See the HBMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HBM Holdings Business Description

Other Exchanges 02142:Hong Kong6XY:Germany
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score

Get the complete analysis for HBMHF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.56
Price
$0.87
GF Value